The human nuclear gene (POLG) for the catalytic subunit of mitochondrial DNA polymerase (DNA polymerase γ) contains a trinucleotide CAG microsatellite repeat within the coding sequence. We have investigated the frequency of different repeat-length alleles in populations of diseased and healthy individuals. The predominant allele of 10 CAG repeats was found at a very similar frequency (approximately 88%) in both Finnish and ethnically mixed population samples, with homozygosity close to the equilibrium prediction. Other alleles of between 5 and 13 repeat units were detected, but no larger, expanded alleles were found. A series of 51 British myotonic dystrophy patients showed no significant variation from controls, indicating an absence of generalised CAG repeat instability. Patients with a variety of molecular lesions in mtDNA, including sporadic, clonal deletions, maternally inherited point mutations, autosomally transmitted mtDNA depletion and autosomal dominant multiple deletions showed no differences in POLG trinucleotide repeat-length distribution from controls. These findings rule out POLG repeat expansion as a common pathogenic mechanism in disorders characterised by mitochondrial genome instability.
Introduction
Mitochondrial DNA (mtDNA) mutations are associated with a wide spectrum of human diseases 1,2 and exhibit a variety of different types of inheritance. Clonal deletions or partial duplications of mtDNA typically manifest sporadically, whereas point mutations are usually maternally inherited. Two other kinds of mtDNA lesion appear to depend upon nuclear rather than mitochondrial genotype: mtDNA depletion [3] [4] [5] and multiple mtDNA deletions with autosomal dominant or recessive inheritance. [6] [7] [8] [9] Autosomal dominant progressive external ophthalmoplegia (ad-PEO) associated with multiple deletions of mtDNA is genetically heterogeneous, with mapped loci on chromosomes 3p14.1-21.2 and 10q24, and other affected families unlinked to either of these. 7, 8 One candidate gene for involvement in mtDNA disorders showing nuclear inheritance is POLG, encoding the catalytic subunit of mitochondrial DNA polymerase (DNA polymerase γ). The gene has been mapped to the region of chromosome 15q24-15q26, [10] [11] [12] and exhibits an unusual feature not shared with its orthologues in mouse, Drosophila or yeast, namely the presence of a trinucleotide (CAG) microsatellite repeat within the N-terminal region of the coding sequence. 11, 13 The sequenced gene ( Figure 1 ) contains 10 consecutive, glutamine-encoding CAG codons, followed by a single CAA and two further CAGs. Instability at trinucleotide repeats is associated with various human disorders, including Huntington's disease (HD), myotonic dystrophy (DM), and several forms of spinocerebellar atrophy (eg SCA1). For review see La Spada 14 and Koshy et al. 15 Such disorders may be conveniently sub-classified according to where the repeat is found in relation to the coding sequence of the affected gene. Where the repeat is found in coding DNA, as here, such disorders are usually dominant, reflecting a gain of function associated with expanded repeat number. Expansions to 35 or more repeats are usually sufficient to create a pathological phenotype in such cases, eg in HD (see Wellington et al 16 for review). Where the repeat is found outside coding DNA (eg in Friedreich ataxia), inheritance is usually recessive, reflecting loss of function, and repeat expansions can be, and usually are, much larger. Different repeatlength alleles of a single gene can be associated with distinct pathological phenotypes, for example in the case of the CAG repeat in the androgen receptor gene, where short 'normal' alleles are associated with enhanced predisposition to prostate cancer, 17 long 'normal' alleles with androgen insensitivity, and expanded alleles ( ³ 40 repeats) with Kennedy's disease. Dominant disorders characterised by repeat expansion also exhibit the phenomenon of anticipation: the progressive increase in repeat length and in disease severity from generation to generation. Expansion of the POLG CAG repeat would be a plausible disease mechanism in disorders characterised by mtDNA instability inherited as an autosomal trait, since expansion of the polyglutamine tract might impair the function of the mitochondrial DNA polymerase in a dominant-negative manner. Interestingly, anticipation has been reported in one family with ad-PEO unlinked to the mapped ad-PEO loci on chromosomes 3p or 10q. 18 A modest polyglutamine expansion might also be associated with apparently sporadic cases of mtDNA rearrangement, or might even promote the mutational events that manifest subsequently as diseases associated with inherited point mutations of mtDNA. In addition, dysfunction of the mitochondrial DNA polymerase not associated with repeat size might be of pathological significance. Repeat-length variation in the POLG gene might therefore provide a useful linkage marker for evaluating the involvement of the gene in diverse human disorders.
In order to investigate the possible role of the POLG gene in human disease, we have studied repeat-length variation at the locus, both in healthy populations and in various groups of patients. Our aim was to look both for gross expansions associated with disease, as well as to examine possibly more subtle relationships between POLG repeat-length and pathological phenotype. The results indicate that POLG repeat expansion cannot be a frequent cause of mitochondrial disease. Diversity at the POLG locus is also lower than optimal for use generally as a linkage marker, but sufficient that the gene can be excluded in specific cases.
Results and Discussion
Nested primers flanking the POLG CAG repeat were designed, based on a region of the coding sequence 11, 13 contained within a single exon (see Figure 1 ). The primers amplified the predicted fragments from genomic DNA (Figure 1 ), as verified by direct sequencing. Testing against the monochromosomal inter-species hybrid and Genebridge 4 radiation hybrid panels 19 confirmed that they detected only the expected gene sequence from chromosome 15q, and not a pseudogene (data not shown). The 5' primer (mip51) was also tested with other, more downstream 3' primers from the same exon of the POLG gene, successfully and routinely amplifying genomic DNA fragments up to 0.6 kb in size (data not shown). This indicates that even grossly expanded CAG repeats (eg of the order of 150) would be detectable.
POLG trinucleotide repeat-length was then evaluated in two groups of healthy controls, plus a number of patient groups, as shown in Table 1 , using a fluorescence-based PCR method. 20 Genotype was also confirmed in many cases by direct sequencing of PCR products or by cloning. The previously reported variant of 10 repeats 11, 13 was found much more frequently than any other allele. In an ethnically diverse sample of 73 unrelated, healthy persons, it was found at a frequency of 88%. In a sample of 61 unrelated, healthy Finns, a genetically isolated and bottlenecked population that has been much exploited in disease linkage studies, the frequency of the common allele was almost the same (89%). Several groups of patients were also studied, including a series of 51 unrelated DM patients from the UK, and a group of 12 unrelated Chinese patients with acute aminoglycoside ototoxicity (AAO), one of whom had the np 1555 mtDNA mutation. The frequency of the common (10-repeat) allele was not significantly different (z-test, P > 0.05) in any group studied, nor was any evidence found for an association between a specific, unusual allele and any of the patient groups investigated. Amongst DM patients, there was furthermore no correlation between disease severity and POLG genotype. The overall frequency of the 10-repeat allele in 214 ethnically diverse, unrelated individuals included in the study was 88%. The next commonest allele was of 11 repeats (7%), with other, rarer alleles ranging from 5 to 13 repeats comprising the remainder. Observed homozygosity values for the common allele are close to equilibrium predictions.
No expanded alleles were observed in healthy controls or in any of the patient groups studied, including the 51 DM subjects. This rules out POLG repeat expansion as a contributory factor in DM, and is consistent with repeat instability being locus-specific in this disorder. Expanded alleles were also absent from diverse patients with mtDNA disorders, as summarised in Table 2 . These results do not exclude the possibility of very large expansions undetectable by conventional PCR, but coding region expansions of the type found in other disorders (i.e. up to several hundred copies) would have been easily observed. Expansions in the CAG repeat of the DMPK gene of over 500 repeat units were easily detected in DM patient DNAs, using primers that amplify a similarly sized (165 bp) fragment spanning the repeat, and otherwise identical materials and methods (data not shown). Most patients we studied were homozygous for the common POLG allele, (except where stated in Table 2 ), but heterozygotes were found amongst several patient groups, in which cases it is possible to exclude even very large expansions undetectable by PCR. Genotyping of the POLG repeat furthermore enabled us to exclude the locus from further consideration in the case of the family with hepatic mtDNA depletion, assuming autosomal recessive inheritance. 21 Linkage studies have also excluded the POLG region of chromosome 15q from involvement in ad-PEO in Finnish, Italian and Swedish families in which it is unlinked to the previously mapped loci on chromosomes 3 or 10 (A Suomalainen 1998, unpublished data).
The amount of heterozygosity at the POLG repeat is probably too low to enable it to be employed as a useful marker in disease linkage studies generally, although it will have utility in specific cases. The fact that a similar pattern of variation is evident in widely scattered populations suggests the possibility of selection, acting to drive the repeat length down (or up) to the modal value of ten CAG repeats. However, all other alleles found amongst patients were also found in controls, hence there is no evidence for association of particular repeat-length variants with any given pathological phenotype.
Methods

DNA Samples
DNA was obtained from blood or muscle biopsy of healthy controls and patients, as described previously, 22 but with proteinase K inactivated by incubation at 92°C for 10 min. All the samples were taken with informed consent. DNA from Chinese patients with acute aminoglycoside ototoxicity was kindly donated by Dr W-Q Qiu (Tiedao Medical College, Shanghai, China), from UK myotonic dystrophy patients by Dr Helen Harley (University of Wales, Cardiff), from Spanish subjects with the np 1555 mtDNA mutation by Dr Ignacio del Castillo (Hospital Ramón y Cajal, Madrid, Spain), and from members of Finnish pedigrees carrying the 
Oligonucleotide primers
Nested oligonucleotides corresponding to regions of the N-terminal coding sequence of POLG, as indicated in Figure 1 , were purchased from Life Technologies (Paisley, Scotland) or DNA Technology (Aarhus, Denmark). For fluorescent PCR 20 one of the primers (mip51) was 5' pre-labelled with ROX (Perkin-Elmer dye) by the manufacturer.
PCR
Unlabelled PCR reactions used primer pairs mip51/ mip31 (126 bp product from reference sequence) or mip51/mip32 (165 bp product) at 0.8 µM each, 200 µM dNTPs (Amersham Pharmacia Biotech, Uppsala, Sweden), plus 0.25 units of Dynazyme thermostable DNA polymerase (Finnzymes, Espoo, Finland) in the manufacturer's buffer. Reactions comprised 30 cycles of denaturation for 1 min at 95°C, annealing for 45 s at 62°C, and extension for 2 min at 72°C (5 min extension in final cycle). Products were analysed by agarose or polyacrylamide gel electrophoresis. For fluorescent PCR, 12.5 µl reactions contained 0.2 µM each primer, 200 µM dNTPs (Amersham Pharmacia Biotech, Uppsala, Sweden), 0.5 µl of DNA template 22 and 0.16 units of Dynazyme thermostable DNA polymerase (Finnzymes, Espoo, Finland) in the manufacturer's buffer, and used the same cycle conditions, except the extension step which was for 1 min only. Reaction products were diluted 1:10 in water, and samples containing 1 µl of diluted PCR product, 12 µl of deionised formanide and 0.15 µl of Tamra Genescan-350 DNA size standards (Perkin-Elmer, Norwalk, CT, USA) were analysed on the ABI 310 Genetic Analyzer (Perkin-Elmer, Norwalk, CT, USA), using the manufacturer's data collection and Genescan analysis software. 20, 23 Cloning and cycle sequencing Unlabelled PCR products were purified on QIAquick spin columns (Qiagen). Cloning used the TA-cloning kit (Invitrogen), and insert-containing plasmids were identified by miniprepping and EcoRI digestion. Cycle sequencing employing the ABI 310 Genetic Analyzer used the Terminator Ready Reaction Kit (PerkinElmer), together with unlabelled mip51 primer (direct sequencing of PCR products) or M13 reverse primer (plasmid sequencing).
